Gilead Sciences: Dawn score and attention ranking
Gilead Sciences scores 50 out of 100 on the Dawn Index, built from 4 signals. It ranks #3 of 7 in Biotechnology (S&P 500), #1 of 4 in Biotechnology (Nasdaq-100), #24 of 57 in Health Care (S&P 500), #2 of 9 in Health Care (Nasdaq-100).
What drives the Gilead Sciences Dawn score?
| Signal | Weight | Score (0 to 100) |
|---|---|---|
| Search scale | 20% | 42 |
| Search momentum | 20% | 54 |
| Site scale | 15% | 51 |
| Site momentum | 10% | 54 |
How does Gilead Sciences compare in Biotechnology (S&P 500)?
| Rank | Brand | Dawn score |
|---|---|---|
| 1 | Moderna | 66 |
| 2 | AbbVie | 52 |
| 3 | Gilead Sciences | 50 |
| 4 | Vertex Pharmaceuticals | 46 |
| 5 | Incyte | 46 |
| 6 | Amgen | 41 |
| 7 | Regeneron Pharmaceuticals | 38 |
Where do the numbers come from?
Search figures are Google search estimates for the brand and its products. Site figures are third-party traffic estimates. A Dawn score measures attention, not revenue.